AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound of formula (I),



(I)

or a pharmaceutically acceptable ~~derivative~~ salt thereof, wherein:

Het ~~represents~~ is 2-pyridinyl or 2-pyrimidinyl;

R^1 ~~represents~~ is H, C_{1-3} alkyl or a nitrogen-containing heterocyclic ring having 5 or 6 ring atoms;

R^2 ~~represents~~ is H, benzyl or C_{1-3} alkyl; and

R^3 ~~represents~~ is H, methyl, methoxy or chloro.

2. (Currently amended) ~~A~~ The compound according to claim 1, or a pharmaceutically acceptable ~~derivative~~ salt thereof, wherein Het ~~represents~~ is 2-pyridinyl.

3. (Currently amended) ~~A~~ The compound according to claim 1, or a pharmaceutically acceptable ~~derivative~~ salt thereof, wherein R^1 ~~represents~~ is 1,2,3-triazolyl.

4. (Currently amended) ~~A~~ The compound according to claim 1, or a pharmaceutically acceptable ~~derivative~~ salt thereof, wherein R^2 ~~represents~~ is H or methyl.

5. (Currently amended) ~~A~~ The compound according to claim 1, or a pharmaceutically acceptable ~~derivative~~ salt thereof, wherein R^3 ~~represents~~ is chloro.

6. (Currently amended) ~~A~~ The compound as claimed in claim 1, or a pharmaceutically acceptable ~~derivative~~ salt thereof, wherein at least one of R^1, R^2 and R^3 ~~represents~~ is a group other than H.

7. (Currently amended) A compound as claimed in claim 1, or a pharmaceutically acceptable ~~derivative~~ salt thereof, wherein R^1 ~~represents~~ is 1,2,3-triazolyl ~~and/or~~ and R^3 ~~represents~~ is chloro.

8. (Currently amended) ~~A compound according to claim 1, selected from~~
2-{4-[4-(2-Ethyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine;
2-{4-[5-Methyl-4-(2-propyl-phenyl)-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine;
2-{4-[4-(2-Isopropyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine
4-(5-Morpholin-4-ylmethyl-4-phenyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-(5-Butyl-4-phenyl-4H-[1,2,4]trizaol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-(4-Phenyl-5-piperidin-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-(5-Methyl-4-phenyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-[4-(4-Methoxy-2-methyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-[4-(4-Chloro-2-methyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-(5-Methyl-4-o-tolyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-[4-(4-Chloro-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-[4-(4-Methoxy-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-[4-(4-Methoxy-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-(4-o-Tolyl-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tatrahydro-2H-[1,2']bipyridinyl;

4-[4-(4-Chloro-2-methyl-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-(4-Phenyl-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-(5-Methyl-4-p-tolyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-[4-(2,4-Dimethyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; or
4-[4-(4-Chloro-2-methyl-phenyl)-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; ~~and~~
or a pharmaceutically acceptable ~~derivatives~~ salt thereof.

9. (Canceled)

10. (Currently amended) A method of treating ~~treatment of~~ a disorder selected from ~~anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlesmerchz, preclampsia,~~ primary dysmennorhea, secondary dysmennorhea, premature ejaculation, or rheumatoid arthritis ~~premature (preterm) labor and Raynaud's disease,~~ comprising administering a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable ~~derivative~~ salt thereof, to a patient suffering from such a disorder.

11. (Currently amended) ~~A~~ The method according to claim 10 wherein the disorder is ~~dysmenorrhoea (primary or secondary)~~ primary dysmennorhea or secondary dysmennorhea.

12. (Currently amended) ~~A~~ The method according to claim 11 wherein the disorder is primary ~~dysmenorrhoea~~ dysmennorhea.

13.-15. (Canceled)

16. (Currently amended) A pharmaceutical ~~formulation including~~ composition comprising a compound according to claim 1 or a pharmaceutically acceptable ~~derivative~~ salt thereof, together with a pharmaceutically acceptable ~~excipients,~~ excipient, diluent or ~~carrier;~~ carrier.

17. (Currently amended) A pharmaceutical ~~product containing a V1a antagonist~~ composition comprising a compound according to claim 1 or a pharmaceutically acceptable ~~derivative~~ salt thereof in combination with a compound selected from (a) an oral contraceptive, (b) a PDE5 inhibitor, (c) an NO donor, (d) L-arginine, or (e) a COX inhibitor, together with a pharmaceutically acceptable acceptable excipient, carrier or diluent ~~as a combined preparation for simultaneous, separate or sequential use in the treatment of dysmenorrhoea~~.